These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36303832)

  • 21. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
    Hardy-Bessard AC; Delva R; Pivot X; Espié M; Dalenc F; Coulon Sfairi MA; Monnier A; Serin D; Veyret C; Lortholary A; Pavlyuk M; Kockler L; Pierga JY
    Bull Cancer; 2012 Jun; 99(6):609-18. PubMed ID: 22665515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taxanes for adjuvant treatment of early breast cancer.
    Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical pharmacology of the taxanes: implications of the differences.
    Gligorov J; Lotz JP
    Oncologist; 2004; 9 Suppl 2():3-8. PubMed ID: 15161985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
    Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taxanes for the treatment of metastatic breast cancer.
    Gradishar WJ
    Breast Cancer (Auckl); 2012; 6():159-71. PubMed ID: 23133315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
    Bi Z; Chen P; Liu YB; Zhao T; Sun X; Song XR; Wang YS
    Breast Cancer Res Treat; 2020 Nov; 184(2):397-405. PubMed ID: 32776291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
    Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
    Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
    Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
    Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
    Sonpavde G; Pond GR; Mullane S; Qu AQ; Di Lorenzo G; Federico P; Necchi A; Rosenberg JE; Bellmunt J; Choueiri TK
    Clin Genitourin Cancer; 2015 Jun; 13(3):250-6. PubMed ID: 25481485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
    Biganzoli L; Aapro M; Loibl S; Wildiers H; Brain E
    Cancer Treat Rev; 2016 Feb; 43():19-26. PubMed ID: 26827689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.
    Mauri D; Kamposioras K; Tsali L; Bristianou M; Valachis A; Karathanasi I; Georgiou C; Polyzos NP
    Cancer Treat Rev; 2010 Feb; 36(1):69-74. PubMed ID: 19945225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer.
    Guastalla JP; Diéras V
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S16-22. PubMed ID: 14661042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of taxanes in the adjuvant treatment of early stage breast cancer.
    Piccart M
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S25-34. PubMed ID: 12868803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study.
    Sawaki M; Ito Y; Hashimoto D; Mizunuma N; Takahashi S; Horikoshi N; Tada K; Kasumi F; Akiyama F; Sakamoto G; Imai T; Nakao A; Hatake K
    Tumori; 2004; 90(1):36-9. PubMed ID: 15143969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity.
    Amaya C; Smith ER; Xu XX
    J Cancer; 2022; 13(7):2362-2373. PubMed ID: 35517405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases.
    Fujimura T; Furudate S; Maekawa T; Kato H; Ito T; Matsushita S; Yoshino K; Hashimoto A; Muto Y; Ohuchi K; Amagai R; Kambayashi Y; Fujisawa Y
    Skin Health Dis; 2023 Feb; 3(1):e180. PubMed ID: 36751323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.